NDC 70518-2780-1 - Naloxone Hydrochloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70518-2780
- Requested NDC
- 70518-2780-1
- Package NDCs from labels
- 70518-2780-1, 70518-2780-0
- Manufacturer
- REMEDYREPACK INC.
- Effective date
- 2022-02-02
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Naloxone Hydrochloride - REMEDYREPACK INC. | REMEDYREPACK INC. | 2022-02-02 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 70518-2780-0 | 2022-02-02 | C162847 | 48780-1 | d6a99b39-47e2-a426-e053-dadaa90af4c2 | 4838e624-7b53-4e45-b42c-ef1213507188 |
| 70518-2780-0 | 2022-01-28 | C162847 | 48780-1 | d6a99b39-47e2-a426-e053-dadaa90af4c2 | 4838e624-7b53-4e45-b42c-ef1213507188 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Par Health USA, LLC | 3ae08e26-223b-4971-b2f1-f1e183a3f930 | 2024-04-11 | Warnings, Adverse reactions | 1191250 F850569PQR |
| Naloxone Hydrochloride | NALXONE HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | 1bef59b9-7d51-4f19-a054-44b8eb6c6398 | 2024-04-10 | Warnings, Adverse reactions | F850569PQR |
| naloxone hydrochloride | NALOXONE HYDROCHLORIDE | Lifestar Pharma LLC | ef647e2a-84e7-4e3e-942a-b6fc250141b6 | 2024-03-04 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | c72a60fb-196d-3f02-e053-2995a90ad906 | 2024-02-22 | Warnings, Adverse reactions | 1191250 F850569PQR |
| Narcan Naloxone HCL | NARCAN NALOXONE HCL | HF Acquisition Co LLC, DBA HealthFirst | 11d770b8-b768-ba3d-e063-6394a90a61a6 | 2024-02-20 | Warnings | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | 94ff1857-06da-7986-e053-2a95a90afb18 | 2024-02-19 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | c90e2d85-ed94-2c00-e053-2a95a90ad2a0 | 2024-01-30 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Actavis Pharma, Inc. | 49350f7e-d613-40a8-8941-a2ec30eafdf3 | 2024-01-30 | Warnings | F850569PQR |
| NALOXONE HCl | NALOXONE HCL | HF Acquisition Co LLC, DBA HealthFirst | f8fcda15-8ba6-e66a-e053-6294a90a385c | 2024-01-28 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HCI | NALOXONE HCI | HF Acquisition Co. LLC, DBA Health First | 73c1bad3-6ac3-8682-e053-2a91aa0a176a | 2024-01-27 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | HF Acquisition Co LLC, DBA HealthFirst | e65e03c1-9a66-b30b-e053-2995a90aeb73 | 2024-01-27 | Warnings, Adverse reactions | 1191250 F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | HF Acquisition Co. LLC, DBA HealthFirst | 74fc593e-ed47-efae-e053-2991aa0a5997 | 2024-01-25 | Warnings, Adverse reactions | ANDA072076 1191250 F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Teva Pharmaceuticals, Inc. | 3a73ee4b-c2a4-496f-be90-9f78c8046062 | 2024-01-01 | Warnings | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | A-S Medication Solutions | 46f27d04-d4d2-4ef1-9cc5-4d58f4056f06 | 2023-12-27 | Warnings | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE NASAL | A-S Medication Solutions | 4517afa1-4b17-4a15-b91b-65b18bd0558f | 2023-11-24 | Warnings, Adverse reactions | F850569PQR |
| NARCAN NALOXONE HCI | NARCAN NALOXONE HCI | HF Acquisition Co LLC, DBA HealthFirst | 784a0e98-c2d6-f845-e053-2991aa0ac4b4 | 2023-10-10 | Warnings, Adverse reactions | F850569PQR |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | A-S Medication Solutions | 0b3b5214-6f91-4bba-82d6-d57b16845df5 | 2023-10-01 | Warnings, Adverse reactions | F850569PQR |
| NARCAN | NALOXONE HYDROCHLORIDE | A-S Medication Solutions | 139c30b9-5600-48f5-8610-0cacd2782398 | 2023-09-28 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Hospira, Inc. | b598c237-032d-4bb5-0e92-50eabd863dac | 2023-06-04 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | A-S Medication Solutions | 3d2dcee4-7510-477b-95a8-9b2afb773984 | 2023-05-23 | Warnings, Adverse reactions | F850569PQR |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.